{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-012576","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.709915+00:00","generated_at":"2026-06-15T21:30:41.420561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)","bullets":["GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.","Non-GAAP adjusted net income $4.2M ($0.09/share) vs adjusted net loss of $0.3M.","Q1 product revenue (NERLYNX) $46.8M, up from $40.7M YoY; royalty revenue $6.0M.","Cash and marketable securities $71.2M at March 31, 2023 vs $81.1M at Dec 31, 2022.","Guidance: FY 2023 net product revenue $205-210M; net income $20-24M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-012576","json":"https://secwatch.observer/filing/0001437749-23-012576.json","markdown":"https://secwatch.observer/filing/0001437749-23-012576.md","text":"https://secwatch.observer/filing/0001437749-23-012576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/pbyi20230502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:30:41.420561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2359112fa26f9baa6497a74eed1a54fbbf3edced","claim":"PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2023 results: revenue $46.8 million, net income $1.4 million, EPS $0.03 per basic and diluted share.","evidence_excerpt":"Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $1.4 million, or $0.03 per basic and diluted share, for the first quarter of 2023, compared to net loss of $3.4 million, or $0.08 per share, for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$46.8 million"},{"label":"Net income","value":"$1.4 million"},{"label":"EPS","value":"$0.03 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2a9e61b90831be287174ec30518dd6eed2fd62af","claim":"PUMA BIOTECHNOLOGY, INC. reported full year 2023 results: revenue $205 - $210 million, net income $20 - $24 million. Guidance initiated.","evidence_excerpt":"Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$205 - $210 million"},{"label":"Net income","value":"$20 - $24 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6b1bdfbb297909b834d39f1aa4b6f43c574add85","claim":"PUMA BIOTECHNOLOGY, INC. reported second quarter 2023 results: revenue $47 - $50 million, net income $0 - $1.5 million. Guidance initiated.","evidence_excerpt":"Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$47 - $50 million"},{"label":"Net income","value":"$0 - $1.5 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}